Abbott, the creator of continuous glucose monitors, launched the new Assist feature at CES 2026. Part of the Libre app, it aims to help people with diabetes take the guesswork out of how food affects ...
Libre Assist 1 uses generative AI to predict how a food choice may affect a person's glucose levels. 2 It then offers actionable and personalized meal guidance 3 to support in-the-moment decisions.
Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in every province ...
In early January 2026, Abbott Laboratories unveiled Libre Assist, an AI-powered feature within its Libre app that helps U.S. diabetes patients predict the glucose impact of meals in real time by ...
Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of hundreds of injuries and seven deaths worldwide—after some sensors showed they ...
A Cuba Libre is a rum and Coke with lime. Only the rum and Coke lacks a certain something—besides the lime. A rum and Coke is the order that you, 21 years and one hour old, stammered at the bartender ...
At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...
Continuous glucose meters (CGMs) aren’t just widgets for the wellness crowd. For many, CGMs are real-time feedback machines for the body, offering glucose trendlines that help people rethink how they ...
Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback